DCIS and invasive ductal carcinoma: understanding the difference

DCIS stands for ductal carcinoma in situ and is non-invasive. Both diagnoses begin in cells lining a duct, but invasion changes how the disease is staged and which additional tests or treatments may be considered.

A mammogram may reveal calcifications that lead to a biopsy, but imaging cannot by itself settle whether cells are confined or invasive. The pathology report provides that distinction and may also describe grade, hormone receptors, and whether the sampled tissue edges contain abnormal cells.

A biopsy showing DCIS can occasionally be followed by a surgical specimen that also contains invasion because surgery examines more tissue. This is why the treatment plan may be refined after the operation.

Management is tailored to the area’s size and position, whether there are several areas, pathology findings, breast size, general health, and personal preferences. DCIS is commonly treated with breast-conserving surgery or mastectomy in selected circumstances. Radiotherapy or hormone-blocking treatment may be discussed after surgery.

For invasive ductal carcinoma, the team also assesses lymph nodes and the possibility of disease beyond the breast. Surgery, radiotherapy, hormone therapy, chemotherapy, or targeted medicines may be combined according to stage and tumour biology.

Arrange a clinical assessment for a new breast or underarm lump, nipple discharge that is bloody or occurs without squeezing, nipple inversion that is new, persistent skin dimpling, breast redness or swelling, or a change in breast shape. These changes have several possible causes and require examination rather than assumptions about cancer.

If you already have a diagnosis, contact your breast team for rapidly increasing swelling, fever, worsening wound redness, uncontrolled pain, or shortness of breath during treatment or recovery.

Ask whether the pathology shows any invasion, what the grade and receptor results mean, whether more imaging is needed, and what surgery is recommended. Clarify whether lymph-node assessment, radiotherapy, or medicines are relevant and when the final pathology could change the plan.